Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol
CONCLUSIONS: Panitumumab treatment provides limited CB in patients with recurrent RAF/RASwt glioblastoma precluding further development of this therapeutic strategy.PMID:38109296 | DOI:10.1093/oncolo/oyad320 (Source: The Oncologist)
Source: The Oncologist - December 18, 2023 Category: Cancer & Oncology Authors: Ilse A C Spiekman Birgit S Geurts Laurien J Zeverijn Gijs F de Wit Vincent van der Noort Paul Roepman Wendy W J de Leng Anne M L Jansen Benno Kusters Laurens V Beerepoot Filip Y F L de Vos Derk-Jan A de Groot Jan Willem B de Groot Ann Hoeben Jan Buter Han Source Type: research
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol
CONCLUSIONS: Panitumumab treatment provides limited CB in patients with recurrent RAF/RASwt glioblastoma precluding further development of this therapeutic strategy.PMID:38109296 | DOI:10.1093/oncolo/oyad320 (Source: The Oncologist)
Source: The Oncologist - December 18, 2023 Category: Cancer & Oncology Authors: Ilse A C Spiekman Birgit S Geurts Laurien J Zeverijn Gijs F de Wit Vincent van der Noort Paul Roepman Wendy W J de Leng Anne M L Jansen Benno Kusters Laurens V Beerepoot Filip Y F L de Vos Derk-Jan A de Groot Jan Willem B de Groot Ann Hoeben Jan Buter Han Source Type: research
Mutational Signature Changes in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal
CONCLUSION: Patients with SCCA demonstrate a high degree of temporal mutational heterogeneity. This supports the hypothesis that ctDNA can serve as a real-time tracking mechanism for solid tumors' molecular evolution in response to therapy. Our findings highlight the potential of ctDNA in identifying emerging actionable mutations, supplementing information from tissue-based genomic assessments. Further research, ideally with larger and multi-institutional cohorts, is needed to validate our findings in this relatively rare tumor type.PMID:38103030 | DOI:10.1093/oncolo/oyad326 (Source: The Oncologist)
Source: The Oncologist - December 16, 2023 Category: Cancer & Oncology Authors: Michael LaPelusa Christopher Cann Kristen K Ciombor Cathy Eng Source Type: research
Mutational Signature Changes in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal
CONCLUSION: Patients with SCCA demonstrate a high degree of temporal mutational heterogeneity. This supports the hypothesis that ctDNA can serve as a real-time tracking mechanism for solid tumors' molecular evolution in response to therapy. Our findings highlight the potential of ctDNA in identifying emerging actionable mutations, supplementing information from tissue-based genomic assessments. Further research, ideally with larger and multi-institutional cohorts, is needed to validate our findings in this relatively rare tumor type.PMID:38103030 | DOI:10.1093/oncolo/oyad326 (Source: The Oncologist)
Source: The Oncologist - December 16, 2023 Category: Cancer & Oncology Authors: Michael LaPelusa Christopher Cann Kristen K Ciombor Cathy Eng Source Type: research
Correction to: The Evolving Landscape of Immune Checkpoint Inhibitors and Antibody Drug Conjugates in the Treatment of Early-Stage Breast Cancer
Oncologist. 2023 Dec 13:oyad330. doi: 10.1093/oncolo/oyad330. Online ahead of print.NO ABSTRACTPMID:38092372 | DOI:10.1093/oncolo/oyad330 (Source: The Oncologist)
Source: The Oncologist - December 13, 2023 Category: Cancer & Oncology Source Type: research
Correction to: The Evolving Landscape of Immune Checkpoint Inhibitors and Antibody Drug Conjugates in the Treatment of Early-Stage Breast Cancer
Oncologist. 2023 Dec 13:oyad330. doi: 10.1093/oncolo/oyad330. Online ahead of print.NO ABSTRACTPMID:38092372 | DOI:10.1093/oncolo/oyad330 (Source: The Oncologist)
Source: The Oncologist - December 13, 2023 Category: Cancer & Oncology Source Type: research
Correction to: The Evolving Landscape of Immune Checkpoint Inhibitors and Antibody Drug Conjugates in the Treatment of Early-Stage Breast Cancer
Oncologist. 2023 Dec 13:oyad330. doi: 10.1093/oncolo/oyad330. Online ahead of print.NO ABSTRACTPMID:38092372 | DOI:10.1093/oncolo/oyad330 (Source: The Oncologist)
Source: The Oncologist - December 13, 2023 Category: Cancer & Oncology Source Type: research
Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer
CONCLUSIONS: In conclusion, monitoring clonal evolution in mCRC by LB may provide an additional treatment line for patients with NeoRAS-wt in advanced disease.PMID:38071748 | DOI:10.1093/oncolo/oyad299 (Source: The Oncologist)
Source: The Oncologist - December 10, 2023 Category: Cancer & Oncology Authors: Joana Albuquerque Diana Neto da Silva Teresa Padr ão Lu ísa Leal-Costa Rita Bizarro Jorge Correia Carlota Baptista Madalena Machete Gil Prazeres In ês Margarido Gon çalo Fernandes Pedro Sim ões Teresa Tim óteo F ábio Lopes Jo ão Godinho Jo ão Mor Source Type: research
Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer
CONCLUSIONS: In conclusion, monitoring clonal evolution in mCRC by LB may provide an additional treatment line for patients with NeoRAS-wt in advanced disease.PMID:38071748 | DOI:10.1093/oncolo/oyad299 (Source: The Oncologist)
Source: The Oncologist - December 10, 2023 Category: Cancer & Oncology Authors: Joana Albuquerque Diana Neto da Silva Teresa Padr ão Lu ísa Leal-Costa Rita Bizarro Jorge Correia Carlota Baptista Madalena Machete Gil Prazeres In ês Margarido Gon çalo Fernandes Pedro Sim ões Teresa Tim óteo F ábio Lopes Jo ão Godinho Jo ão Mor Source Type: research
Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer
CONCLUSIONS: In conclusion, monitoring clonal evolution in mCRC by LB may provide an additional treatment line for patients with NeoRAS-wt in advanced disease.PMID:38071748 | DOI:10.1093/oncolo/oyad299 (Source: The Oncologist)
Source: The Oncologist - December 10, 2023 Category: Cancer & Oncology Authors: Joana Albuquerque Diana Neto da Silva Teresa Padr ão Lu ísa Leal-Costa Rita Bizarro Jorge Correia Carlota Baptista Madalena Machete Gil Prazeres In ês Margarido Gon çalo Fernandes Pedro Sim ões Teresa Tim óteo F ábio Lopes Jo ão Godinho Jo ão Mor Source Type: research
Methotrexate Scarcity Among Children's Oncology Group Institutions: Results of a Multinational Survey
Oncologist. 2023 Dec 9:oyad323. doi: 10.1093/oncolo/oyad323. Online ahead of print.ABSTRACTShortages of curative chemotherapy agents for children and adults with cancer are ubiquitous. These shortages directly result in compromised outcomes, increased medication errors, heightened cost to health systems, and patient deaths. Methotrexate is a staple of many curative childhood cancer regimens and is frequently in scarcity. No national guidance to manage methotrexate and other chemotherapy shortages exists. To assess the effect of the current methotrexate shortage, a multinational survey of Children's Oncology Group (COG) mem...
Source: The Oncologist - December 9, 2023 Category: Cancer & Oncology Authors: Sarah Menig Olga Militano Andrew Ostrenga M Brooke Bernhardt Brittany Lee Yoram Unguru Source Type: research
Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma
CONCLUSION: In ET-refractory HR+ HER2-negative mILC, single-agent CAP demonstrated superior PFS compared to TAX. Our findings highlight the potential benefit of CAP in this patient subset, warranting further investigation through prospective trials.PMID:38070191 | DOI:10.1093/oncolo/oyad317 (Source: The Oncologist)
Source: The Oncologist - December 9, 2023 Category: Cancer & Oncology Authors: Jason A Mouabbi Wei Qaio Yu Shen Akshara Singareeka Raghavendra Debasish Tripathy Rachel M Layman Source Type: research
Methotrexate Scarcity Among Children's Oncology Group Institutions: Results of a Multinational Survey
Oncologist. 2023 Dec 9:oyad323. doi: 10.1093/oncolo/oyad323. Online ahead of print.ABSTRACTShortages of curative chemotherapy agents for children and adults with cancer are ubiquitous. These shortages directly result in compromised outcomes, increased medication errors, heightened cost to health systems, and patient deaths. Methotrexate is a staple of many curative childhood cancer regimens and is frequently in scarcity. No national guidance to manage methotrexate and other chemotherapy shortages exists. To assess the effect of the current methotrexate shortage, a multinational survey of Children's Oncology Group (COG) mem...
Source: The Oncologist - December 9, 2023 Category: Cancer & Oncology Authors: Sarah Menig Olga Militano Andrew Ostrenga M Brooke Bernhardt Brittany Lee Yoram Unguru Source Type: research
Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma
CONCLUSION: In ET-refractory HR+ HER2-negative mILC, single-agent CAP demonstrated superior PFS compared to TAX. Our findings highlight the potential benefit of CAP in this patient subset, warranting further investigation through prospective trials.PMID:38070191 | DOI:10.1093/oncolo/oyad317 (Source: The Oncologist)
Source: The Oncologist - December 9, 2023 Category: Cancer & Oncology Authors: Jason A Mouabbi Wei Qaio Yu Shen Akshara Singareeka Raghavendra Debasish Tripathy Rachel M Layman Source Type: research
The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023
Oncologist. 2023 Dec 4:oyad322. doi: 10.1093/oncolo/oyad322. Online ahead of print.ABSTRACTThe 5th Kidney Cancer Research Summit was a hybrid event hosted in Boston, MA in July 2023. As in previous editions, the conference attracted a wide representation of global thought leaders in kidney cancer spanning all stages of clinical and laboratory research. Sessions covered tumor metabolism, novel immune pathways, advances in clinical trials and immunotherapy, and progress toward biomarkers. The abstract presentations were published as a supplement in The Oncologist (https://academic.oup.com/oncolo/issue/28/Supplement_1). Aimin...
Source: The Oncologist - December 4, 2023 Category: Cancer & Oncology Authors: Toni K Choueiri Sumanta K Pal Bryan Lewis Susan Poteat Kevin Pels Hans Hammers Source Type: research
